Vaxcyte Corporate Presentation

Next-Generation Vaccine Pipeline Focus on Superior PCV Franchise with Novel, Early Stage Pipeline to Follow VAX-24 VAX-XP VAX-A1 Lead Candidate 24-Valent PCV Next-Generation >30-Valent PCV Novel Group A Strep Vaccine TARGET INFANTS & ADULTS POPULATION • . Anticipate IND filing in Q1:22(1) • Anticipate Phase 1/2 data readout in the adult population in late '22-early '23(1) Published preclinical POC vs. PrevnarⓇ13 (PCV13) and PneumovaxⓇ23 (PPV23) in the journal Vaccine 6 (1) Guidance provided as of November 10, 2021. • INFANTS & ADULTS VAX-PG о Novel Therapeutic Periodontitis Vaccine CHILDREN & ADULTS ADULTS PCV13 • Initiated IND-enabling activities in 2H:21 • Anticipate selecting final vaccine candidate in 1H:22(1) ● Supported with grant from CARB-X Completed preclinical POC vs. and PPV23 Investing to maximize PCV franchise optionality and value

View entire presentation